Ivan O Rosas Selected Research

Syndecan-2

1/2022	Mesenchymal stromal cell-derived syndecan-2 regulates the immune response during sepsis to foster bacterial clearance and resolution of inflammation.
1/2021	CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis.
1/2019	Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness.
1/2018	Syndecan-2 Attenuates Radiation-induced Pulmonary Fibrosis and Inhibits Fibroblast Activation by Regulating PI3K/Akt/ROCK Pathway via CD148.
10/2013	Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-β receptor I internalization and inhibiting transforming growth factor-β1 signaling.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ivan O Rosas Research Topics

Disease

27	Idiopathic Pulmonary Fibrosis 11/2022 - 06/2007
24	Fibrosis (Cirrhosis) 06/2022 - 01/2008
24	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2022 - 03/2010
14	Lung Diseases (Lung Disease) 01/2022 - 01/2008
14	Interstitial Lung Diseases (Interstitial Lung Disease) 04/2020 - 07/2009
13	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 09/2012
11	Rheumatoid Arthritis 01/2020 - 04/2013
10	Emphysema 01/2022 - 03/2011
9	Inflammation (Inflammations) 01/2022 - 07/2009
9	Lung Injury 01/2022 - 03/2012
9	Lymphangioleiomyomatosis (Lymphangiomyomatosis) 10/2021 - 01/2014
6	Pneumonia (Pneumonitis) 05/2022 - 03/2012
5	COVID-19 05/2022 - 01/2021
5	Neoplasms (Cancer) 10/2020 - 01/2014
4	Disease Progression 01/2018 - 10/2012
3	Tuberous Sclerosis (Bourneville's Disease) 12/2019 - 01/2014
3	Dyspnea (Shortness of Breath) 03/2019 - 04/2012
2	Hermanski-Pudlak Syndrome (Hermansky-Pudlak Syndrome) 06/2022 - 01/2018
2	Infections 05/2022 - 01/2016
2	Hypoxia (Hypoxemia) 04/2022 - 10/2015
2	Sepsis (Septicemia) 01/2022 - 12/2013
2	Respiratory Insufficiency (Respiratory Failure) 10/2021 - 01/2014
2	Critical Illness (Critically Ill) 01/2021 - 12/2013
2	Wounds and Injuries (Trauma) 10/2020 - 05/2016
2	Pulmonary Arterial Hypertension 01/2020 - 01/2018
2	Pulmonary Hypertension 01/2020 - 01/2018
2	Vascular Diseases (Vascular Disease) 01/2020 - 09/2017
2	Bronchiolitis Obliterans Syndrome 01/2017 - 01/2017
2	Carcinogenesis 01/2017 - 01/2014
1	Severe Acute Respiratory Syndrome 05/2022
1	Thrombosis (Thrombus) 04/2022
1	Sclerosis 01/2022
1	Lung Neoplasms (Lung Cancer) 01/2022
1	Bronchiectasis 01/2022
1	Arthritis (Polyarthritis) 01/2022

Drug/Important Bio-Agent (IBA)

15	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2008
12	Proteins (Proteins, Gene)FDA Link 04/2022 - 01/2008
12	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022 - 03/2010
9	SmokeIBA 01/2022 - 04/2012
6	lipoarabinomannan (LAM)IBA 10/2021 - 01/2014
6	CollagenIBA 05/2021 - 03/2010
5	RNA (Ribonucleic Acid)IBA 04/2022 - 01/2020
5	Carbon MonoxideIBA 01/2022 - 07/2015
5	Syndecan-2IBA 01/2022 - 10/2013
4	tocilizumab (atlizumab)FDA Link 05/2022 - 01/2021
4	AntibodiesIBA 01/2020 - 07/2009
4	Sirolimus (Rapamycin)FDA Link 11/2018 - 01/2012
3	Messenger RNA (mRNA)IBA 04/2022 - 01/2016
3	AntigensIBA 01/2022 - 04/2013
3	Blood Proteins (Serum Proteins)IBA 01/2020 - 07/2009
3	Hydroxyproline (4 Hydroxyproline)IBA 01/2020 - 01/2016
3	CytokinesIBA 01/2020 - 07/2009
3	AutoantibodiesIBA 01/2020 - 04/2013
3	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2020 - 10/2013
3	TOR Serine-Threonine KinasesIBA 12/2019 - 09/2015
3	brassIBA 03/2019 - 07/2014
2	Monoclonal AntibodiesIBA 11/2022 - 01/2021
2	Peptides (Polypeptides)IBA 04/2022 - 09/2015
2	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2021
2	C-Reactive ProteinIBA 01/2022 - 07/2009
2	ChemokinesIBA 01/2022 - 07/2009
2	Biological ProductsIBA 12/2021 - 01/2014
2	Oxygen (Dioxygen)IBA 11/2021 - 01/2008
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 09/2015
2	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2021 - 01/2021
2	LigandsIBA 01/2021 - 10/2015
2	Extracellular Matrix ProteinsIBA 01/2020 - 06/2007
2	pirfenidoneIBA 11/2019 - 02/2015
2	Methotrexate (Mexate)FDA LinkGeneric 03/2019 - 01/2019
2	GlucocorticoidsIBA 01/2019 - 01/2018
2	Mucin-5BIBA 11/2018 - 06/2013
2	GoldIBA 01/2018 - 09/2015
2	trans-sodium crocetinate (crocetin)IBA 01/2017 - 01/2014
2	Vascular Endothelial Growth Factor DIBA 01/2017 - 03/2014
2	nintedanibIBA 01/2016 - 02/2015
2	InflammasomesIBA 01/2016 - 03/2012
2	Protein Isoforms (Isoforms)IBA 01/2016 - 04/2013
2	Galectin 3 (LGALS3)IBA 01/2016 - 03/2014
2	Matrix Metalloproteinases (MMPs)IBA 08/2014 - 07/2009
2	EnzymesIBA 04/2013 - 07/2009
2	ImmunosorbentsIBA 04/2013 - 07/2009
1	Myosins (Myosin)IBA 06/2022
1	Monomeric GTP-Binding ProteinsIBA 06/2022
1	GuanineIBA 06/2022
1	Ferritins (Ferritin)IBA 01/2022
1	cyclic citrullinated peptideIBA 01/2022
1	MetallothioneinIBA 01/2022
1	Proteoglycans (Proteoglycan)IBA 01/2022
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022
1	Anti-Citrullinated Protein AntibodiesIBA 01/2022
1	SyndecansIBA 01/2022
1	fibrin fragment D (D-dimer)IBA 01/2022
1	Small Cytoplasmic RNAIBA 12/2021
1	Hyaluronic Acid (Hyaluronan)IBA 11/2021
1	remdesivirIBA 11/2021

Therapy/Procedure

6	Lung Transplantation 04/2020 - 11/2015
5	Therapeutics 01/2018 - 02/2013
2	Transplantation 01/2021 - 07/2009
1	Traction 01/2022
1	Aftercare (After-Treatment) 01/2022